

REMARKS

This application is a national phase filing under 35 U.S.C. §371 of International Application No. PCT/JP2004/019226 filed May 30, 2007. The PCT application, with an International Filing date of December 22, 2004, claims priority to Japanese Patent Application Serial No. 2003-425706, filed December 22, 2003. At the time the application was filed, claims 1-6 were pending and claims 1, 4 and 5 were amended in a Preliminary Amendment filed with the application. In their March 12, 2010 Response, Applicants amended claims 1 and 6, canceled claims 2 and 4, and added new claims 7-10. On December 3, 2010 Applicants filed a Request for Continued Examination (RCE) and a Response to a Final Office Action, wherein Applicants amended claims 1 and 6-9. Currently, Applicants amend claims 1 and 7 and cancel claims 5 and 6. Claims 1, 3, 7, 8 and 10 are currently pending in the application.

The Examiner's rejections are addressed below. Reconsideration of the application and allowance of all claims pending herein are respectfully requested in view of the following remarks.

Rejections under 35 U.S.C. §103:

The Office Action states that claim 6 is rejected as unpatentable over Konetschny et al. (Development of a Highly Sensitive and Specific Enzyme-Linked Immunosorbent Assay for Detection of ADAMTS-13 in Human Plasma, Blood 102 (11) Abstract #4062 (November 16, 2003) in view of Scheiflinger et al. (US 2004/02114346).

Applicant brings to the Examiner's attention that claim 6 has been canceled in this response.

Rejections under 35 U.S.C. §112:

The Office Action states that claims 1, 3, 5, 7, 8 and 10 are rejected under 35 U.S.C. §112, first paragraph, as not being enabled for their full scope. The Office Action also states that the present invention is enabled for the MAb WH10, MAb WH63.1, and WH2-22 1A antibodies.

Applicant directs the Examiner's attention to amended claims 1 and 7, which have now been limited to the MAb WH10, MAb WH63.1, and WH2-22 1A antibodies.

CONCLUSION

In view of the foregoing, reconsideration and withdrawal of the rejections are respectfully requested. There being no other outstanding issues, it is believed that the application is in condition for allowance, and such action is respectfully requested.

No fees are believed due. However, the Commissioner is hereby authorized to charge any fees that may be required, or credit any overpayment, to Deposit Account No. 08-1935, Reference No. 2352.014.

If a telephone conference would be of assistance in advancing the prosecution of the subject application, Applicants' undersigned attorney invites the Examiner to telephone him at the number provided.

Respectfully submitted,



Brian E. Reese
Attorney for Applicants
Reg. No. 64,538

Dated: September 20, 2011

HESLIN ROTHENBERG FARLEY & MESITI P.C.
5 Columbia Circle
Albany, New York 12203
Telephone: (518) 452-5600
Facsimile: (518) 452-5579
Customer Number: 23405